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Abstract
Background: Postmarketing surveillance is routinely conducted to monitor performance of pharmaceuticals and testing
devices in the marketplace. However, these surveillance methods are often done retrospectively and, as a result, are not
designed to detect issues with performance in real-time.
Methods and Findings: Using HIV antibody screening test data from New York City STD clinics, we developed a formal,
statistical method of prospectively detecting temporal clusters of poor performance of a screening test. From 2005 to 2008,
New York City, as well as other states, observed unexpectedly high false-positive (FP) rates in an oral fluid-based rapid test
used for screening HIV. We attempted to formally assess whether the performance of this HIV screening test statistically
deviated from both local expectation and the manufacturer’s claim for the test. Results indicate that there were two
significant temporal clusters in the FP rate of the oral HIV test, both of which exceeded the manufacturer’s upper limit of the
95% CI for the product. Furthermore, the FP rate of the test varied significantly by both STD clinic and test lot, though not
by test operator.
Conclusions: Continuous monitoring of surveillance data has the benefit of providing information regarding test
performance, and if conducted in real-time, it can enable programs to examine reasons for poor test performance in close
proximity to the occurrence. Techniques used in this study could be a valuable addition for postmarketing surveillance of
test performance and may become particularly important with the increase in rapid testing methods.
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Introduction
Postmarketing surveillance is conducted to monitor the
performance of a pharmaceutical or testing device recently
introduced to the marketplace. Because postmarketing surveillance
includes data from the general population, it has the ability to
detect rare events, which are difficult to detect in pre-licensure
studies, such as a clinical trial involving a relatively small number
of subjects. In the United States, the Food and Drug Adminis-
tration (FDA) routinely conducts postmarketing surveillance and
has the ability to remove a drug or device from market because of
new evidence of problems with efficacy or safety [1]. Postmarket-
ing surveillance has been carried out on rapid testing devices, such
as those used to test for the presence of human immunodeficiency
virus (HIV) antibody [2,3]; however, a critique of these types of
surveillance activities is that they are often performed retrospec-
tively, once issues with test performance have been repeatedly
observed [4]. Here we propose a formal method, routinely utilized
in syndromic surveillance [5], that can be used prospectively to
improve the sensitivity and timeliness of postmarketing surveil-
lance of screening test performance. This method was developed
using data from New York City’s sexually transmitted disease
(STD) clinics.
In October 2005, the New York City Department of Health and
Mental Hygiene (NYC DOHMH) observed unexpectedly high
false-positive (FP) rates in the oral fluid-based testing for HIV
antibody (OraQuick Advance Rapid HIV-1/2) in several of its 10
STD walk-in clinics. Variations in the false-positive rate had not
been previously observed in New York City when whole blood
specimens were used with the OraQuick Advance Rapid HIV-1/2
test for HIV antibody. In the United States, all clinical laboratory
testing devices are regulated by the Centers for Medicare and
Medicaid Services through the Clinical Laboratory Improvement
Amendments (CLIA) program. The Orasure oral HIV test used in
NYC STD clinics during this time was deemed simple enough to
perform to garner a CLIA waiver [6]. As a result, the test was
exempt from most CLIA requirements, although the FDA requires
facilities to adhere to quality assurance guidelines for CLIA-waved
tests to ensure that mistakes are minimized and FDA restrictions
for sale of these tests are followed [7]. A review of the specificity
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that from 2005 to 2008 there were two distinct peaks in the false-
positive (FP) rate, first in late 2005 and again in late 2007 [8]
(Figure 1). In fact, from October 2007 to April 2008, the median
specificity of the oral test was 99.5%, which is below the
manufacturer’s claim for the product (95% CI=99.6–99.9%) (4).
This followed similar observations of intermittently low test
specificity of the oral HIV test from clinics in other US states,
namely Minnesota and California (2, 3). As a result of the issues in
2005, New York City suspended use of the oral HIV test for three
weeks in late 2005 and then reintroduced oral fluid-based testing
only in conjunction with immediate follow-up rapid whole blood
testing after any reactive oral fluid test result (7). When a drop in
specificity of the oral HIV test occurred again, in 2008, DOHMH
suspended use of oral fluid for HIV-1/2 antibody screening in the
spring of 2008, and has since returned to using the same rapid test,
but only with whole blood specimens.
In this study, we assessed whether the FP rate of the oral HIV
test rose significantly above expectation in each of NYC’s STD
clinics from 2005 to 2008. Here we defined expectation in two ways.
In syndromic surveillance an expected value is often calculated
using a baseline period in the observed data. Calculation of this
expected value tells us what is normally seen in our population.
However, it may also be of interest to determine whether the FP
rate differs from an acceptable limit, as is often a goal in
postmarketing surveillance [1]. Therefore, we attempted to answer
both whether the FP rate rose above what was historically
experienced in NYC’s STD clinics, as well as whether the FP rate
rose above the manufacturer’s claim of the upper limit of the FP
rate for the product. We further assessed whether any increase in
the FP rate was related to factors occurring at the clinic level,
including operator performance. This method can also be used in
real-time, and the ability to conduct prospective postmarketing
surveillance could substantially improve the ability to detect issues
with performance and the response time to reassess the suitability
of such products for the marketplace.
Methods
Over 170,000 oral fluid-based HIV-1/2 antibody tests were
performed in the 10 DOHMH STD clinics in New York City
from March 1st, 2005 to June 30th, 2008. Positive rapid oral tests
were considered preliminary and were followed up with a
confirmatory Western blot (WB) test. Any preliminary-positive
test that was found to be WB-negative was deemed to be a false-
positive oral test. Data were collapsed by date to calculate a daily
FP rate. Information on test date, clinic, and test operator were
recorded for each test performed, as well as the manufacturer’s
product lot number.
SaTScan
TM software, v7.0 was applied retrospectively to
prospective data collected over the study period to detect temporal
clusters in the FP rate of the oral HIV screening test. Data were
assumed to be Bernoulli-distributed and significance was assessed
through Monte Carlo simulation [9].
Figure 1. False-positive rate of the rapid HIV test, March 1st 2005 to June 30
th 2008. Daily false-positive rate of the oral fluid rapid HIV test,
evaluated in New York City’s 10 DOHMH STD clinics from March 1st 2005 to June 30
th 2008. The moving average was calculated by taking the
unweighted average across a 28-day moving window of the FP rate.
doi:10.1371/journal.pone.0012231.g001
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the manufacturer’s upper limit for the FP rate for the test (0.004),
the FP rate was artificially inflated to equal 0.004 over the entire
study period. SaTScan was then run on these artificial data,
including 999 Monte Carlo simulations. The log likelihood ratio
(LLR) for the most likely cluster from the observed data was then
ranked among the LLRs of the 999 simulations from the artificial
dataset to determine the probability that the observed cluster
would have been detected given a FP rate of 0.004. STD clinic was
also included as a covariate in a separate scan to determine
whether any temporal clusters persisted after adjusting for the
effect of clinic. Furthermore, a scan was performed to test the
variation by time and clinic simultaneously to assess whether any
clinic exhibited a temporal cluster in the FP rate, after adjusting
for its own baseline level.
Data were aggregated by test lot for all lots with more than 10
tests. A scan was then performed on these data, stratified by lot, to
determine whether any single test lot had a higher than expected
FP rate.
Finally, to assess whether the FP rate varied by test operator, a
kernel smoothing function was applied to the data aggregated by
test operator for all operators who performed at least 100 tests. A
weighted linear regression line was also fit to these data to test
whether the number of tests performed by an operator was a
predictor of the FP rate. The regression line was weighted by the
total number of tests performed. Both the kernel smoothing
function and regression analysis were performed using R software
v2.9 (cran.r-project.org). All data were analyzed anonymously.
Neither IRB approval nor informed consents were obtained for
this study.
Results
An average of 181 oral HIV tests were performed daily in the 10
DOHMH STD clinics over the study period (SD=51.6). The
median observed FP rate over this time was 0.003 (Specific-
ity=99.7%), which is within the manufacturer’s claim (99.6–
99.9%) for the product. However, two distinct clusters of high FP
rates were detected over the study period (Figure 1). The largest
cluster signal occurred from October 30, 2007 to April 21, 2008
(LLR=80.5), p=0.001). The specificity of the oral test during this
time was 99.3%, representing a FP rate of 0.007. A second cluster
signal was detected when the analysis was limited to dates before
the beginning of the first cluster (10/30/07). This second cluster
occurred from September 1, 2005 to March 23, 2006 (LLR=63.8,
p=0.001). The specificity during this time was 99.4% (FP rate
=0.006).
When comparing the LLR of the first cluster to the 999
simulations in which the data were artificially inflated to have an
average FP rate of 0.004, the observed cluster ranked first in
Monte Carlo simulation, representing a p-value of 0.001.
Furthermore, when comparing the second cluster to the 999
simulations in which the revised baseline period (i.e., 3/1/05 to
10/30/07) was inflated to have an average FP rate of 0.004, the
observed cluster again ranked first.
We found the FP rate to vary by clinic (chi-square test of
difference, x
2=82.0, 9df, p,0.001), so the expected FP rate was
adjusted for the effect of clinic in the temporal scan. When this was
done, the primary cluster period increased in length by ten days,
lasting from October 30, 2007 to May 1, 2008 (LLR=99.8,
p=0.001).
To further investigate whether certain clinics had clusters of
high FP rates during the study period, a clinic-level temporal
analysis was performed. This analysis produced unique temporal
signals in five of the city’s ten STD clinics (Table 1). All five of
these clinic-level signals occurred within either the primary or the
secondary citywide temporal signal.
There were 94 HIV test kit lots used in NYC during the study
period (minimum tests per lot=10, maximum=10,614). The test
lot-level scan of high FP rates produced six signals, indicating that
the FP rate was significantly higher than expectation for six test
lots during the study period. Furthermore, all six lot-level signals
coincided with either the primary or secondary citywide signal. It
is worth noting that all but one of these six test lots were used at
multiple STD clinics and the number of FP tests recorded from
each lot varied by clinic. For example, one lot was used at nine of
the ten clinics with a FP rate of between 0% and 2.4% at each.
Finally, test operator was found to be only a marginally significant
predictor of the FP rate in the weighted regression analysis
(ß=22.7E-7, p=.055).
Discussion
Results of our analysis indicate that the temporal scan method
was able to detect distinct time periods when the FP rate exceeded
both what was usually seen in New York City’s STD clinics, as well
as what the manufacturer claimed for the product. Monitoring
variations in this test’s FP rate is important because with rare
diseases like HIV, a small decrease in specificity can lead to a large
decrease in the positive predictive value (PPV: the proportion of
subjects with a positive test who are correctly diagnosed) of a test.
For example, a drop in specificity of the oral test from 99.8% to
99.5% translates to a decrease in PPV from 76% to 49% in the
New York City STD clinic population. This suggests that when the
specificity dropped to 99.5%, more than half of all patients with an
HIV-preliminary-positive rapid test result were, in fact, not HIV-
positive. When a preliminary-positive screening test is observed,
multiple actions are taken that impose a large burden both
logistically for the clinic, and more importantly, personally for the
patient. Since the NYC DOHMH had instituted the immediate
re-testing of preliminary oral positives patients with finger-stick
whole-blood tests, the counselors were able to discuss with the
patient that the observed discordant tests were most likely due to a
false-positive result. However, the additional wait time for the
confirmatory HIV test result becomes an added stress for both the
patient and the counselors who are delivering this message. Timely
action in correcting poor test or operator performance is,
therefore, critical to maintaining accurate public health screening.
The two detected clusters correspond well with the observations
made by astute NYC DOHMH staff at the time. However, a
strength of this scan analysis that cannot be achieved by simple
Table 1. Clinic-level temporal signals of the daily false
positive rate of the Orasure rapid oral HIV test performed in




Clinic Cluster start Cluster end LLR p-value
4 10/22/07 4/16/08 39.046 0.001
7 9/20/05 1/12/06 32.124 0.001
2 2/14/08 4/28/08 21.383 0.001
9 12/3/07 4/21/08 20.887 0.001
1 8/26/05 2/17/06 16.707 0.001
Showing clinic-level signals with a p-value of less than 0.01 only.
doi:10.1371/journal.pone.0012231.t001
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many simulations of the data to see if chance could explain the
findings. In this case, it is very unlikely that the existence of these
two clusters occurred by chance alone. Thus, our method has the
ability to formally test the probability of seeing what was observed
in the data in real-time. A further strength of this method is that
because it calculates a single test statistic for the most likely cluster
in the observed data, it accounts for the multiple testing problems
that can arise when many tests are performed at once in a single
day at several locations. With this said, our analysis only includes
data from New York City, whereas this oral HIV test is performed
in clinics across the United States. Therefore, to completely
account for issues of multiple testing, data from all test sites during
this time period would need to be analyzed concurrently.
The fact that five of the ten STD clinics signaled during the
study period indicates that the FP rate in the oral test was not only
heterogeneous over time, but also by clinic, or another factor that
varied by clinic. These results indicate that including clinic as a
covariate improves the sensitivity of the scan analysis to detect
clinic-level signals. Identifying clinic-level signals also helps to
narrow down the possible location and causes of the observed poor
test performance. Two notable factors that may vary by clinic are
test lot and test operator. Other studies investigated both test lot
and operator as potential causes of variation in the performance of
the oral HIV test [2,3] and found no associations. Our results
generally support these studies in finding little evidence that the
test’s performance varied by operator. However, our analysis does
provide evidence that the FP rate varied by test lot. Other
unmeasured factors, such as test storage and handling practices or
data entry could be causes of the clinic-level variability in test
performance; however we were not able to directly measure this.
Future testing programs may want to record these types of data in
order to include these factors in test surveillance.
We have proposed a simple statistical method of detecting
temporal changes in the specificity of a screening test. While this
method was applied retrospectively to prospective data, when test
results are available electronically, our methods could easily be
applied prospectively, which would allow for real-time cluster
detection. SaTScan software is free and can be run from within a
SAS software session, which can be set-up to run automatically
daily, weekly, or at any other time aggregation. A similar temporal
scan analysis has been part of New York City’s syndromic
surveillance activities for several years [10]. As part of this system,
SaTScan is used to detect temporal clusters in several unique time
series, including ED visits, EMS calls and drug sales. Our method
is well suited for use with medical screening, such as mammog-
raphy, which is known to have low specificity and high variability
in radiologist interpretation [11], and could also be used on any
screening test that is performed in conjunction with confirmatory
testing of diseases such as HIV, syphilis, influenza, and malaria,
among others. Furthermore, these methods could be used as a tool
in postmarketing surveillance to assess the validity of a
manufacturer’s claims for their product. Great strides have been
made in the development and use of rapid testing, which has
helped to reduce the financial and technical barriers in health
screening, with particular promise for the developing world. And
while the specificity of HIV rapid tests is higher than tests for many
other conditions, the performance of these screening tests is often
not equal to more rigorous laboratory testing [12,13] and
confirmatory testing remains essential for diagnosis. Developing
methods for monitoring the performance of rapid screening tests
over time will become particularly important as the use of these
tests continues to rise in the future.
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